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CHAPTER I 
INTRODUCTION 
Oral drug delivery is the simplest and easiest way of administering drugs. Because of the 
greater stability, smaller bulk, accurate dosage and easy production, solid oral dosages forms 
have many advantages over other types of oral dosage forms. Therefore, most of the new 
chemical entities(NCE) under development these days are intended to be used as solid dosage 
form that originate an effective and reproducible in vivo plasma concentration after oral 
administration. 
 In some cases, a small modification in the chemical structure of the compound led to a 
slight change in biological activity, whereas in some other compounds, even a minor 
modification led to extreme variations. This led to the recognition of the fact that a great deal of 
knowledge is required for studying the many factors that affect biological and therapeutic 
activity of the administered drug. 
 In recent years, however, the number of new products introduced by the Food and Drug 
administration, and partly because there are not too many new products left to be discovered. 
Therefore a large number of manufacturers have shifted, in part, their attention to 
marketing either old product in new dosage forms (termed, new drug –delivery systems) or in the 
same dosage form as generic products. It is for this reason, that many multinational companies 
are involved in the manufacture of generic products at the present time, although, in the past, a 
generic product was the domain of mainly "generic companies".  
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Therefore, the availability of a large number of generic products has given further 
impetus to research in accessing biological availability of the drug from the administered dosage 
form. With a large number of generic as well as multi-national companies competing for a larger 
share of the generic product business, it is no wonder that such terms as bioavailability, drug 
product selection, generic equivalency, therapeutic efficacy, and drug substitution have become 
common house-hold words. 
Bioavailability is defined as the rate and extent of drug absorption. An intravenously 
administered dose of a drug in a aqueous solution (without any added ingredient such as 
buffering agents, preservatives, solubilizing agents, etc.) is considered to be completely available 
to the biological system because the entire drug dose is placed differently into the blood stream.              
It is conceivable, however, that a commercial formulation of an intravenous dose may not 
necessarily be completely available, if added substances in the formulation form a complex, or 
are absorbed to the drug. The drug from an extravascularly administered dose, on the other hand, 
may or may not be completely available. 
 A number of reasons may be responsible for the lack of complete availability of drug 
from an extravascularly administered dosage form. These include: incomplete absorption of the 
drug dose, inactivation of part of the administered dose in the biological environment, 
metabolism of part of the drug dose at the absorption site, or other similar reasons. Since biologic 
response is a result of an interaction between the drug substance and the functionally important 
molecules (receptors) in the living system, unavailability of a portion of the administered drug 
from the dosage form may result in variation in the expected therapeutic response1. 
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ABSORPTION OF DRUGS FROM SOLID DOSAGE FORMS: 
When a drug is given orally in the form of a tablet, capsule, or suspension, the rate of 
absorption is often controlled by how rapid the drug dissolves in the fluids at the absorption site. 
In other words, dissolution rate is often the rate- limiting (slowest) step in the sequence,  
 
Solid dosage form 
↓ 
Solid drug particles 
↓ 
Drug in solution  
↓ 
Drug in systemic circulation 
 
When dissolution is the controlling step in the over all process, absorption is said to be 
dissolution rate limited. Whenever a drug is more rapidly absorbed from solution than from a 
solid dosage form, it is likely that absorption is rate limited by dissolution. 
A general relationship describing the dissolution process was first observed by Noyes and 
Whitney. The Noyes-Whitney equation states that: 
dc/dt = ks (Cs ¯¯¯ C) 
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Where, 
• dC/dt - dissolution rate, 
• k - Constant, 
• S - Surface area of the dissolving solid, 
• Cs- solubility of the drug or chemical in the solvent, and 
• C- Concentration of the material in the solvent at time t. 
The constant k is equal to D/h, where D is the diffusion coefficient of the dissolving 
material, and h is the thickness of the diffusion layer.  
The diffusion layer, like the unstirred water layer in the intestine, is a thin, stationary film 
of solution adjacent to the surface of the solid. The layer saturated with drug; drug concentration 
in the layer is equivalent to Cs.  The term (Cs –C) represents the concentration gradient between 
the diffusion layer and the bulk solution. If absorption is dissolution rate limited, C is negligible 
compared to Cs. Under these conditions, the above equation may be written as:   
dc/dt = DSCs /h 
The above equation describes a diffusion-controlled dissolution process. It is envisioned 
that when the solid is introduced to the dissolution medium, the drug rapidly saturates the 
diffusion layer. Drug molecules diffuse from the saturated layer to the bulk (the slow step in the 
dissolution process) but are immediately replaced in the diffusion layer from the solid surface.  
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 This equation is an oversimplified representation of the dynamics of dissolution; 
nevertheless, it is qualitatively useful and permits a consideration of the effects of certain 
important factors of dissolution rate2. 
Fundamentally this process is controlled by the relative affinity between the molecules of 
the solid substance and those of the solvent. The extent to which the dissolution proceeds under a 
given set of experimental conditions is referred to as the solubility of the solute in the solvent.  
The amount of matter that passes into solution so as to establish equilibrium at constant 
temperature and so produce a saturated solution is known as the solubility. 
PREDICTION OF SOLUBILITY3: 
 Probably the most sought after information about solutions in formulation problem is 
‘what is the best solvent for a given solute. Theoretical prediction of precise solubility is an 
involved and occasionally unsuccessful operation but, from knowledge of the structure and 
properties of solute and solvent, you can make an educated guess. This guess is best expressed in 
subjective terms, such as ‘very soluble’ or ‘sparingly soluble’, as prescribed below in Table: 1. 
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Description 
 
 
                       Approximate weight of solvent(g) 
Necessary to dissolve 1g of solute 
 
Very soluble 
Freely soluble 
Soluble 
Sparingly soluble 
Slightly soluble 
Very slightly soluble 
Practically insoluble 
 
< 1 
Between 1and 10 
Between 10 and 30 
Between 30 and 100 
Between 100 and 1000 
Between 1000 and 10,000 
>10,000 
 
Often (particularly in pre or early formulation) this is all the information that the 
formulator requires. A more precise value can be obtained later in the development process. 
SOLUBILITY4                    
 An important physiochemical property of a drug substance is solubility, especially 
aqueous system solubility. A drug must possess some aqueous solubility for therapeutic efficacy. 
For a drug to enter systemic circulation and exert a therapeutic effect, it must first be in solution.  
Relatively insoluble compounds often exhibit incomplete or erratic absorption. If the 
solubility of the drug substance is less than the desirable, consideration must be given to improve 
its solubility. 
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The methods to accomplish this depend on the chemical nature of the drug and the type 
of the drug product under consideration. Chemical modification of the drug into salt or ester 
forms is frequently used to increase solubility. 
A drug’s solubility is usually determined by the equilibrium solubility method, by which 
an excess of the drug is placed in a solvent and shaken at a constant temperature over a long 
period until equilibrium is obtained. Chemical analysis of the drug content in solution is 
performed to determine degree of solubility4.  
DISSOLUTION 
Variations in the biologic activity of a drug substance may be brought about by the rate at 
which it becomes available to the organism. In many instances, dissolution rate, or the time it 
takes for the drug to dissolve in the fluids at the absorption site, is the rate-limiting step in 
absorption. This is true for drugs administered orally in solid forms such as tablets, capsules, or 
suspensions, and for those administered intramuscularly.  
When the dissolution rate is the rate-limiting step, anything that affects it will also affect 
absorption. Consequently, dissolution rate can affect the onset, intensity, and duration of 
response and control the overall bioavailability of the drug from the dosage form. 
 The dissolution rate of drugs may be increased by decreasing the particle size. It may 
also be increased by increasing its solubility in the diffusion layer. The most effective means of 
obtaining higher dissolution rates is to use a highly water-soluble salt of the parent substance. 
Although a soluble salt of a weak acid will precipitate as the free acid in the bulk phase of an 
acidic solution, such as gastric fluid, it will do so in the form of fine particles with a large surface 
area 
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BIOAVAILABILITY ENHANCEMENT THROUGH ENHANCEMENT OF DRUG 
SOLUBILITY OR DISSOLUTION RATE5: 
There are several ways by which drug solubility or the dissolution rate can be enhanced. 
Some of widely used methods are as follows, 
 Micronization 
 Nanonisation 
 Supercritical fluid recrystallization 
 Spray freezing into liquid(SFL) 
 Evaporative precipitation into aqueous solution (EPAS) 
 Use of surfactants 
 Use of salt forms 
 Use of precipitation Inhibitors 
 Alteration of pH of the Drug Microenvironment 
 Use of Amorphs, Anhydrates, Solvates and Metastable Polymorphs 
 Solvent Deposition 
 Precipitation 
 Selective Adsorption on Insoluble Carriers 
 Solid Solutions 
 Eutectic Mixtures 
 Solid dispersions 
 Molecular encapsulation with cyclodextrins. 
 Use of solid solutions, 
 Use of eutectic mixtures and Use of solid dispersions 
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In all these cases, the solute is frequently a poor water-soluble drug acting as the guest 
and the solvent is a highly water-soluble compound or polymer acting as a host or carrier.                                       
A solid solution is a binary system comprising of a solid solute molecularly dispersed in a 
solid solvent. Since the two components crystallize together in a homogeneous one phase 
system, solid solutions are also called as molecular dispersions or mixed crystals.  
Because of reduction in particle size to the molecular level, solid solutions show greater 
aqueous solubility and faster dissolution than eutectics and solid dispersions. They are generally 
prepared by fusion method whereby a physical mixture of solute and solvent are melted together 
followed by rapid solidification. Such systems, prepared by fusion, are often called as melts. e.g. 
griseofulvin-succinic acid. The griseofulvin from such solid solution dissolves 6 to 7 times faster 
than pure griseofulvin. 
SOLID DISPERSIONS: 
These are generally prepared by solvent or co-precipitation method whereby both the 
guest solute and the solid carrier solvent are dissolved in a common volatile liquid solvent such 
as alcohol. The liquid solvent is removed by evaporation under reduced pressure or by freeze-
drying which results in amorphous precipitation of guest in a crystalline carrier.  
Thus, the basic difference between solid dispersions and solid solutions/eutectics is that 
the drug is precipitated out in an amorphous form in the former as opposed to crystalline form in 
the latter; e.g. amorphous sulphathiazole in crystalline urea.  
Other polymers such as PEG and Crospovidone are also employed to prepare solid 
dispersions of poorly water-soluble drugs such as Nifedipine and Itraconazole.         
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Preparation of solid dispersions also presents several limitations- 
 Since the carrier is hydrophilic and the drug is hydrophobic, it is difficult to find a 
common solvent to dissolve both components. 
 The product is often soft, waxy and processes poor compressibility and flowability. 
 Physical stability of the solid dispersion. 
 Difficulty in preparation of a reproducible product. 
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CHAPTER II 
SOLID DISPERSION -A REVIEW 
Introduction6 
The oral route remains the favorite route of drug administration due to its convenience, 
good patient compliance and low medicine production costs. Consecutively for a drug to be 
absorbed into the systemic circulation following oral administration, the drug must be dissolved 
in the gastric fluids.  
The active pharmaceutical ingredient in a solid dosage form must undergo dissolution 
before it is available for absorption from the gastrointestinal tract. For hydrophobic drugs, the 
dissolution process acts as the rate-controlling step and, which determines the rate and degree of 
absorption. As a result many hydrophobic drugs show erratic and incomplete absorption from the 
gastrointestinal tract of animals and humans.  
 Bioavailability of poorly water-soluble hydrophobic drugs [Class II in Biopharmaceutics 
Classification System] is restricted by their solubility and dissolution rate. The dissolution rate of 
these drugs can be improved by decreasing particle size, decreasing crystallinity, and increasing 
the surface area.  
Several studies have been carried out to enhance the dissolution rate of drugs by 
diminishing the particle size, by creating nano- and microparticles.  In this technique, the drug is 
dissolved in an organic solvent followed by soaking of the solution by a high-surface-area carrier 
such as silica. Here, agglomeration of the drug particles is prevented due to the binding of drug 
to the carrier.  
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 Drug release is a crucial and limiting step for oral drug bioavailability, particularly for 
drugs with low gastrointestinal solubility and high permeability. By improving the drug release 
pattern of these drugs, it is possible to increase their bioavailability and reduce side effects.  
Solid dispersions are one of the most successful techniques to progress drug release of poorly 
soluble drugs.  
SOLID DISPERSIONS7 
First generation solid dispersion 
The first description of solid dispersions was from Sekiguchi and Obi in 1961. They 
renowned that the formulation of eutectic mixtures improves the rate of drug release and, 
therefore the bioavailability of poorly water soluble drugs. In the same decade, a number of solid 
dispersions were described using poorly water soluble drugs, such as sulfathiazole and 
chloramphenicol using urea as high water soluble carrier.  
These solid dispersions fashioned faster release and higher bioavailability than 
conventional formulations of the same drugs. The small particle size and the better wettability of 
the drug were the major reasons for the experimental improvements in bioavailability. Later, 
Levy and Kaning developed solid dispersion systems, containing mannitol as carrier, by 
developing solid solutions through molecular dispersions in place of using eutectic mixtures. The 
observed Improvements were credited to faster carrier dissolution, releasing microcrystals or 
particles of drug. These solid dispersions, which could be designed as first generation solid 
dispersions (Figure 1), were equipped using crystalline carriers.                       
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Second generation solid dispersions 
In the late sixties it was experimental that solid dispersions, where the drug was 
maintained in the crystalline state, might not be as effective as the amorphous, because the first-
mentioned were more thermodynamically stable. Therefore, a second generation of solid 
dispersions appeared, containing amorphous carrier instead of crystalline. 
Fully synthetic polymers include povidone (PVP), poly ethylene glycols (PEG) and    
Poly methacrylates. Natural product based polymers are mainly composed by cellulose 
derivatives, such as hydroxyl propyl methylcellulose (HPMC), ethylcellulose or hydroxyl propyl 
cellulose or starch derivates, like cyclodextrins. 
Third generation solid dispersions   
Recently, it has been shown that the dissolution pattern can be improved if the carrier has 
surface activity or self-emulsifying properties, therefore third generation solid dispersions 
appeared. These include a surfactant carrier, or a mixture of amorphous polymers and surfactants 
as carriers. These third generation solid dispersions are proposed to achieve the highest degree of 
bioavailability for poorly soluble drugs and to stabilize the solid dispersion, avoiding drug 
recrystallization.            
HPMC was also associated with poloxamer and poly oxy ethylene hydrogenated castor 
oil to prepare an amorphous felodipine solid dispersion. The addition of surfactants in the 
formulation containing a polymeric carrier may help to avoid precipitation and/or protect a fine 
crystalline precipitate from agglomeration into much larger hydrophobic particles. 
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Figure-1: The classification of solid dispersions 
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POORLY WATER SOLUBLE DRUG 
 
 
Tablet/capsule                         Dosage Form                                           solid 
dispersion/solution       
 
 
Disintegration  Disintegration 
 
 
Large Solid Particles colloidal particles/ 
(Usually 5-100 microns)                                             Fine Oily Globules (Usually < 1 microns) 
                                                                                                          
Low dissolution rate ABSORPTION                     higher dissolution rate 
           
Figure 2 : Schematic representation of the bioavailability enhancement of a 
poorly water soluble drug by solid dispersion compared with conventional 
tablet or capsule. 
Dosage form 
DRUG IN   
G.I. TRACT 
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The advantage of solid dispersion, compared with conventional capsules and tablet 
formulations, is shown schematically in Figure-3 .8   From conventional capsules and 
tablets, the in vitro release rate is limited by the size of the primary particles formed after 
the disintegration of dosage forms. In this case ,an average particle size of 5 µm is 
generally the lower limit,although higher particle sizes are preferred for ease of handling , 
formulation, and manufacturing . On the other hand, if a solid dispersion or a solid 
solution is used , a portion of the drug dissolves instantaneously to saturate the 
gastrointestinal fluid, and the excess drug precipitates out as fine colloidal particles or 
oily globules of submicron size8.  
 The advantages of solid dispersion system includes,  
a. An increase in aqueous solubility of the drug because of its very small particle 
size. 
b. A possible solubilization effect on the drug by the carrier in the surrounding 
diffusion layer. 
c. A reduction or absence of agglomeration of drug particles 
d. Excellent wettability and dispersability of the exposed drug paticles in the 
gastrointestinal fluids. 
e. Formation of metastable polymorphic forms 
However,solid dispersion does have certain disadvantages which include change in 
crystallinity and decrease dissolution rate on aging.moisture and temperature have more 
deterioting effect on these systems and handling is not easy due to tackiness. 
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PREPARATION TECHNIQUES OF SOLID DISPERSION9 
A.SOLVENT EVAPORATION METHOD 
In this method, physical mixture of two components are dissolved in a common solvent 
and followed by the evaporation of solvent. This method has been used for a long time in the 
preparation of solid solution or mixed crystals of organic or inorganic compounds. 
Advantages of this method: 
1. Low temperature requirement for the preparation of dispersion 
2. Thermal decomposition of drugs and carriers can be prevented. 
Disadvantages of this method: 
1. The higher cost of production 
2. Incomplete removal of solvent 
3. Selection of common solvent 
B. MELTING METHOD 
The physical mixture of drug and water-soluble carrier was heated to melt and the molten 
mixture was then cooled and solidified mass was crushed, pulverized and sieved. The melting 
point of a binary system depends on its composition and proper manipulation of drug carrier 
ratios. Decomposition should be avoided due to fusion time and rate of cooling. 
C. KNEADING METHOD 
The physical mixture of drug an carrier were triturated using small quantity of organic 
solvent and water mixture, usually alcohol and water (1:1 v/v). The slurry is kneaded for 45 
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minutes and dried at 450C. The dried mass is pulverized and sieved through sieve no 60 and the 
fraction was collected.  
Advantages of this method: 
1. Low temperature requirement for the preparation of dispersion 
2. Usage of organic solvent is less. 
D. MELTING SOLVENT METHOD 
It involves dissolving the drug in a suitable solvent and incorporation of the solution 
directly into the molten carrier. The solvent or drug may not be miscible with the carrier. The 
liquid solvent used may affect the polymeric form of the rug precipitate in solid dispersion. 
Advantages of this method: 
1. Low temperature requirement for the preparation of dispersion 
2. Usage of organic solvent is less. 
E. SPRAY DRYING 
Spray drying technique finds more important utility in the pharmaceutical industry due to 
rapid drying and specific physical characters such as particle size and shape of the product. It is a 
cost effective process as compared to that of freeze drying resulting in the production of fine 
solid particles. The operation conditions and design of the drier depends upon the drying 
characteristics of the product and powder specifications. 
F. LYOPHILIZATION TECHNIQUE 
This technique was an alternative to solvent evaporation method. Here the drug and 
carrier are dissolved in common solvent, frozen and sublimed to obtain a lyophilized molecular 
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dispersion. Lyophilization technique was used to improve the solubility and dissolution rate of 
many drugs. 
G. MELT AGGLOMERATION PROCESS 
This technique has been use to prepare solid dispersion where a binder acts as a carrier. 
The solid dispersion is prepare by heating binder, drug and excipient to a temperature above the 
melting point or spraying the dispersion of drug in the molten binder on the heated excipient 
using a high shear mixer. The effect of binder type, method of preparation and particle size are 
the critical factors influencing the solid dispersion preparation by this method. These parameters 
results in various dissolution rates, mechanism of agglomerate formation and growth, 
agglomerate size and distribution. 
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CHAPTER III 
LITERATURE REVIEW 
Literature reviews on solid dispersions of a number of drugs have been attempted and 
reports on them have been well documented. 
1. Heike Bleya et al., were prepared solid dispersions by a melting method from the water-
insoluble model drugs carbamazepine and nifedipine and polyethylene glycol 1500 (PEG 
1500) or 1:1 mixtures of PEG 1500 and the polymers polyvinylpyrrolidone (PVP 30, PVP 
12), polyvinylpyrrolidone-co-vinylacetate (PVPVA) and Eudragit EPO (Eudragit),and were 
characterized by dissolution, powder X-ray diffractometry. 
2. Jani Rupal et al., developed Solid dispersions (SDs) of Aceclofenac in PEG-6000, PVP 
were prepared by solvent evaporation method. The solid dispersion was characterized for 
physical appearance, solubility and IR. FTIR study reveled that drug was stable in SDs. 
Solubility of Aceclofenac from SDs increased in distilled water.  
3. Anette Seo et al., were prepared solid dispersion by melt agglomeration were agglomerates 
containing solid dispersions of diazepam as poorly water-soluble model drug in order to 
evaluate the possibility of improving the dissolution rate. Lactose monohydrate was melt 
agglomerated with polyethylene glycol (PEG) 3000 or Gelucire® 50/13 (mixture of 
glycerides and PEG esters of fatty acids). Different drug concentrations, maximum 
manufacturing temperatures, and cooling rates were investigated. It was established to be 
possible to increase the dissolution rate of diazepam by melt agglomeration.. 
4. Betageri.G.V et al., were studied the preparation of solid dispersions and lyophilization of 
the dispersions designed to enhance the solubility. Solid dispersions of GLY (Glyburide) 
were prepared using polyethylene glycol 4000 (PEG 4000), PEG 6000 and a mixture of 
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PEG 4000 and PEG 6000 (1:1 mixture). Dissolution studies showed a significant raise in 
dissolution of GLY when dispersed in PEGs. 
5. Angela Nedelcu et al.,were prepared inclusion complexes of repaglinide by using                 
ß-cyclodextrin and ß-cyclodextrin derivatives.dissolution studies showed a significant raise 
in dissolution of repaglinide when dispersed in ß-cyclodextrin. 
6. Sandrien Janssens et al., were designed Kollicoat IR, a new pharmaceutical excipient 
developed as a coating polymer for instant release tablets, as a carrier in solid dispersions of 
Itraconazole. The solid dispersions were prepared by hot stage extrusion. DSC and X-ray 
powder diffraction were used to characterize the miscibility of the drug and the carrier. The 
results of this study show that Kollicoat IR® is a capable excipient for the formulation of 
solid dispersions of Itraconazole prepared by hot stage extrusion. 
7. Renata Jachowicz et al., were prepared Solid dispersions of different ratios of Gelita 
collagel as the carrier and lactose were prepared by the spray drying method. In vitro release 
studies have revealed that by preparing solid dispersions the dissolution rate and the 
solubility of oxazepam increase obviously, independent of the ratio of drug, carrier and 
lactose. The properties of the solid dispersions were characterized by X-ray diffraction and 
polarizing microscopic studies. 
8. Karel Six et al., were investigated the performance of three new solid dispersion 
formulations of itraconazole in human volunteers in comparison with Sporanox®, the 
marketed form. Solid dispersions were prepared with itraconazole (40%, w/w) and HPMC 
2910, Eudragit E100 or a mixture of Eudragit E100-PVPVA64 were manufactured by hot-
stage extrusion and filled in gelatin capsules.  
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9. Anne Mari Juppo et al., were evaluated the formation of solid solution particles in the 
Solution Enhanced Dispersion by Supercritical fluids (SEDS) process from a model drug 
and two different types of carriers, mannitol and Eudragit† E100. SEDS was shown to be an 
effective process for forming intimate blends and solid solutions for the drug and two 
different types of carriers. 
10. Shailesh V. Biradar et al., were developed a solid dispersion of Roxithromycin (ROX), a 
class IV drug has 50% absolute oral bioavailability due to poor aqueous solubility. Their 
study dealt with exploring the effect of homogenization, homogenization pursued by freeze 
drying and homogenization followed by spray drying in the presence of solubilizers on drug 
solubility and dissolution rate.  
11. Okonogi.S et al., were studied to develop the dissolution rate of a sparingly water soluble 
drug, ofloxacin, by solid dispersion systems with urea and mannitol. DSC, PXRD analysis 
and IR Spectroscopy were performed to evaluate the physicochemical properties.  
12. Bhaskar Chauhan et al., were formulated Solid dispersions (SDs) of glibenclamide 
(GBM); a poorly water-soluble drug and polyglycolized glycerides (Gelucire®) with the aid 
of silicon dioxide (Aerosil® 200); as an adsorbent, were prepared by spray drying 
technique.  This study demonstrated the high potential of spray drying technique for 
obtaining stable free flowing SDs of poorly water-soluble drugs using polyglycolized 
glycerides carriers with the aid of silicon dioxide as an adsorbent. 
13.  Adamo Fini et al., were prepared a number of systems at five compositions (5, 10, 20, 30 
and 40% w/w) of diclofenac/N-(2-hydroxyethyl) pyrrolidine salt and acidic diclofenac in 
PEG6000 and Gelucire 50/13, as physical mixtures and as solid dispersions. Powder X-ray 
diffractograms for the systems examined show shifted and normal peaks, suggesting that the 
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drug is present inside the samples in different physical states. Drug solubility into the 
carriers increases with temperature and thermograms show only the melting point peak of 
the carriers.  
14. Guy Van den Mooter et al., were developed solid dispersions made up of itraconazole and 
Inutec SP1, a new polymeric surfactant, by spray drying and hot-stage extrusion. 
Differential scanning calorimetry (DSC) and X-ray powder diffraction (XRD) were used to 
evaluate the miscibility of the components of the dispersions. This study reveals the 
potential of the new polymeric surfactant as a carrier in the formulation of solid dispersions 
for poorly soluble drugs.  
15. Naji M. Najib et al., worked to provide a valuable insight into the mechanism of 
dissolution rate enhancement of diflunisal caused by its dispersion in polyethylene glycol 
(PEG).  
16. Xingwang Zhang et al., were studied to characterize lansoprazole (LSP) /PVP solid 
dispersion prepared by a fluid-bed coating technique. In vitro dissolution test in pH 7.4 
phosphate buffer indicated that the dissolution rate was dramatically enhanced even at an 
LSP/PVP ratio of 1/1.75 or with more PVP. DSC and powder X-ray diffractometry proved 
the absence of crystallinity in LSP/PVP solid dispersion at a ratio of 1/2 or with more PVP.  
17. Masataka Saito et al., were studied to improve the solubility and,  physical characteristics 
of griseofulvin (GF) solid dispersions with saccharides as the dispersion carrier using a roll 
mixing method. This study suggested that the saccharides with a high molecular weight are 
useful carriers for solid dispersions. 
18. Huiju Liu et al., were designed the dissolution of indomethacin (INM) into polymer 
excipient Eudragit® E PO (E PO) melt at temperatures lower than the melting point of INM 
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using a laboratory-size, twin-screw counter rotating batch internal mixer. The outcome 
showed that the dissolution rate increased with increasing the mixer set temperature, or the 
screw rotating speed.  
19. Tomoyuki Watanabe et al., were studied the states of interaction between indomethacin 
(IM) and polyvinylpyrrolidone (PVP) in an amorphous solid dispersion prepared by co-
grinding were compared with those between IM and silica nanoparticles.  
20. Carina Dahlberg et al., were demonstrated the ability of drugs to persuade the wetting of 
solid dispersion tablets in unexpected ways. Five model drugs of different water solubility 
and ability to interact with the involved polymers were incorporated in hydrophilic polymer 
matrices, made of either hydroxypropyl methylcellulose (HPMC) or polyvinyl pyrrolidone 
(PVP).However, the solid dispersions containing HPMC deviated from this regular 
behaviour and displayed contact angles below those of the pure compounds involved, either 
drug or polymer. 
21. Anguiano-Igea.S et al., were examined the effect of molecular weight of polyethylene 
glycols (PEGS) and drug/PEG ratio on the structure and dissolution rates of the solid 
dispersions with clofibrate.  The dissolution rates of clofibrate improved as the molecular 
weight of PEG increased, but the best results were obtained with PEG 20000.  
22. Yalcin Ozkan et al., were examined the release of etodolac from various molecular weight 
fractions of polyethylene glycol (PEG) solid dispersions. Solid dispersions of etodolac were 
prepared in different molar ratios of drug:carrier by using solvent and melting methods. The 
dissolution rate of etodolac is increased in all of the solid dispersion systems compared to 
that of the pure drug and physical mixtures. 
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23. Nattha Kaewnopparat et al., were prepared solid dispersions(SD)of curcumin polyvinyl 
pyrrolidone in the ratio of 1:2, 1:4, 1:5, 1:6, and 1:8  in an attempt to increase the solubility 
and dissolution. Both solubility and dissolution of curcumin solid dispersions were 
appreciably greater than those observed for physical mixtures and intact curcumin. 
24. Arvind K. Bansal et al., were developed a solid dispersion method for the drug Irbersartan. 
Irbesartan (IBS) is a hydrophobic drug with poor aqueous solubility and dissolution rate. 
Solid dispersions of IBS were ready with both small molecules (tartaric acid and mannitol) 
and polymeric additives (polyvinylpyrrolidone, PVP, and hydroxypropyl methylcellulose, 
HPMC).  Thermal methods were used to evaluate the miscibility of the drug and additives.   
25. Yogesh Pore et al., were studied the dissolution behaviour of a poorly water-soluble drug, 
tadalafil, from its solid dispersion systems with poloxamer 407 has been investigated. Solid 
dispersion systems of tadalafil were prepared with poloxamer 407 in 1:0.5, 1:1.5 and 1:2.5 
ratios using the melting method. Studies established the presence of strong hydrogen 
bonding interactions, a significant decrease in crystallinity and the possibility of existence of 
amorphous entities of the drug.   
26. Anette Seo et al., were aimed to prepare solid dispersions of diazepam by melt 
agglomeration as diazepam is a poorly water-soluble model drug so as to evaluate the 
possibility of improving the dissolution rate. Lactose monohydrate was melt agglomerated 
with polyethylene glycol (PEG) 3000 or Gelucire® 50/13 (mixture of glycerides and PEG 
esters of fatty acids) as meltable binders in a high shear mixer.  It was found to be feasible to 
increase the dissolution rate of diazepam by melt agglomeration. A higher dissolution rate 
was obtained with a lower drug concentration. 
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27. Minsuk Lee et al., were desired to increase the solubility of sibutramine freebase, the solid 
dispersion was prepared using a fluid-bed granulator. The solid dispersion containing 
sibutramine freebase was characterized by DSC and powder X-ray diffraction (XRD).  The 
dissolution rate of sibutramine solid dispersion was considerably increased about 70% than 
sibutramine freebase. 
28. Punitha.S et al., were developed a solid dispersion of celecoxib by Physical triturating 
method, Solvent evaporation and fusion method were prepared using 1:1, 1:3 and 1:5 ratios 
of drug and polymer (urea). The prepared dispersion showed marked increase in the 
saturation solubility and dissolution rate of celecoxib than that of pure drug.  
29. Gopal Venkatesh Shavi et al., were formulated solid dispersions of Gliclazide using 
different water soluble polymers such as polyethylene glycol 4000 (PEG 4000), 
polyethylene glycol 6000 (PEG 6000) using fusion method and polyvinyl pyrrolidone K- 30 
(PVP K 30) by solvent evaporation method. Pharmacokinetic studies of optimized 
formulation were compared with pure drug and marketed formulation in wistar rats.   
30. Margarit.M.V et al., were analyzed the physicochemical characteristics of solid dispersions 
of pizotifen malate and povidone (Kollidon 12) at different proportions. The results were 
correlated with findings for physical mixtures with the same proportions. 
31. Biswal.S et al., were prepared solid dispersions (SDs) of Gliclazide with polyethylene 
glycol (PEG) 8000 and compare them with SDs in PEG 6000.  Gliclazide SDs containing 
changeable concentrations of PEG 8000 were ready using the fusion – solvent technique, 
and their phase solubility behavior and dissolution in 0.1N HCl were assessed at 37oC. The 
solubility of gliclazide improved with increasing amount of PEG 8000 in aqueous medium.  
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32. Patel B.P et al., were prepared solid dispersions of Cinnarizine by using PEG 4000,           
PVP K30  exhibited enhanced dissolution rate of Cinnarizine. 
33. Jachowicz.R et al., were formulated the ternary solid dispersions of ketoprofen with 
Macrogol and kollagen hydrolizate derivative as carriers , in which diverse methods of solid 
dispersion preparation (melting, solvent method, different cooling), different proportions of 
drug:carriers and molecular weight of Macrogol were tested.  The raise in the amount of 
released ketoprofen from solid dispersion pellets was 3.8-times bigger than from the pellets 
containing the drug alone. 
34. Hirofumi Takeuchi et al., were prepared a Solid dispersion particle of tolbutamide (TBM) 
by formulating nonporous (Aerosil 200 (hydrophilic), Aerosil R972 (hydrophobic)) or 
porous (Sylysia 350 (hydrophilic), Sylophobic 200 (hydrophobic)) silica as a carrier and 
applying the spray-drying (SD) or evaporation (Eva) method.  
35. Nora Anne Urbanetz et al., were prepared a solid dispersion of nimodipine by 
incorporation of a drug in a carrier by melt embedding with in the carrier material. As the 
dispersivity of the drug is of outstanding importance for its dissolution characteristics, 
parameters which are supposed to influence crystallinity and dispersivity, It is found that the 
absence of crystalline drug material in solid dispersions containing nimodipine and 
polyethylene glycol 2000 is the must for a high dissolution rate and a significant  
supersaturation in the dissolution medium.   
36. Purvis T. et al., were prepared rapidly dissolving Repaglinide powders produced by the 
Ultra-rapid freezing process.These formulations showed a faster rate of dissolution and 
show greater bioavailability. 
 
 28 
37. Arias.M.J.  et al., were demonstrated a solid dispersion technique for triamterene as a 
method for enhancing the Gl absorption of the drug triamterene has been explored so as to 
acquire better dissolution characteristics and better bioavailability. In vitro release profiles 
have been considered and quantified in terms of dissolution efficiency over the first 30 min 
(DE3,,) and dissolution percentage over the first 30 min (DP,,). The results revealed that 
there were no significant differences between the three polyethylene glycols (PEGS) under 
test. 
38. Wei Wu et al., were developed the solid dispersions of silymarin (SM) with 
polyvinylpyrrolidone (PVP) by a one-step fluid-bed coating technique. The process 
involved the spray application of the ethyl alcohol solution of SM and PVP and subsequent 
deposition of the coprecipitates onto the non-pareil pellets in drying air flow in a fluid-bed 
coater.  The results demonstrated that the dissolution of PVP/SM solid dispersions was 
enhanced greatly at PVP/SM ratios of over 4/1. The results indicate that the fluid-bed 
coating technique has the potential use in the preparation of solid dispersions. 
39. Madhuri Newa et al., were developed binary solid dispersion of ibuprofen using poloxamer 
188. By melt agglomeration method. And concluded that the solubility, dissolution and 
absorption rate of ibuprofen were enhanced by preparing ibuprofen solid dispersion with 
poloxamer 188. 
40. Monica Rao et al., were prepared solid dispersion of simvastatin by using PVP K30 and    
poloxamer 188. It is a concluded to improved bioavailability due to enhancement in rate and 
extend of drug release. 
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CHAPTER IV 
AIM OF   WORK 
Repaglinide is a poorly water soluble drug and it belongs to Class II in Biopharmaceutics 
Classification System and which is prescribed as an anti diabetic drug for the treatment of type II 
(non-insulin dependent) diabetes mellitus. Solid dispersions of repaglinide 
would increase the solubility, bioavailability of drug and improve drug efficiency.   
 Repaglinide is  a carbamoyl methyl benzoic acid derivative used  as  an oral 
antidiabetic   medication in the  treatment  of  type II diabetes, that  act  primarily  by  
decreasing  insulin  resistance. 
No attempt has been made to increase the solubility of Repaglinide through solid 
dispersion methods. Hence the dissolution  of  Repaglinide in  citro phosphate buffer PH 5 may  
increase  its  absorption   and  finally   bioavailability  may  be  enhanced  for the conventional 
dosage formulations. 
Therefore the aim of present study is to develop a solid dispersion method 
for Repaglinide to enhance its solubility. So that the formulation dissolves completely in the citro 
phosphate buffer PH 5 and ensures the complete absorption and bioavailability of Repaglinide. 
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  CHAPTER V 
PLAN OF WORK 
PART I 
1. Determination of λmax for Repaglinide in citro phosphate buffer PH 5. 
2. Plotting of calibration curve for the drug in citro phosphate buffer  PH 5.                                     
PART-II  
1. Formulation of solid dispersions of Repaglinide using different concentration                 
of carriers by melting method and solvent evaporation method. 
PART-III 
1. Determination of drug content of all the formulations 
PART -IV  
1. Invitro release studies of the formulated repaglinide solid dispersions by using citro 
    Phosphate buffer PH 5 as dissolution medium in USP-type-I method (basket type). 
 
PART-V 11,12,13 
1.  IR studies of drug and solid dispersions to determine the interaction between carriers and 
drug. 
2. Differential scanning calorimetry (DSC) studies of selected formulations to determine the 
status of the drug and carrier. 
3. Powder x-ray diffraction (PXRD) studies of selected formulations to determine crystallinity 
of the drug. 
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CHAPTER VI 
MATERIALS AND EQUIPMENTS 
  
MATERIALS USED 
  
1. Drug-Repaglinide                                 - Gift sample from Dr. Reddy’s Laboratories 
2. PEG-6000                                             -   S. D. Fine Chemicals 
3. Poloxamer 188                                      -    Madras Pharma 
4. PVP k30                                                                 -      Nice Chemicals 
5. Crospovidone                                        -    Nice Chemicals 
6. Methanol                                               -      Nice Chemicals 
7. Disodium hydrogen orthophosphate    -     Qualigens 
8. Citric acid monohydrate                        -    Qualigens 
EQUIPMENTS USED 
 
1. Electronic Balance             -       A&D Company, Japan 
2. UV Visible Spectrophotometer         -       UV Pharma Spec 1700, Shimadzu, Japan 
3. Dissolution Apparatus                       -      LABINDIA Disso 2000 
4. Water Bath                                        -      Mc Dalal & Co 
5. Rotary Flask Shaker            -      SECOR INDIA. 
6. Hot Air Oven                                    -       SICO 
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   CHAPTER VII 
DRUG PROFILE 40,41,42,43 
Repaglinide is an oral blood glucose-lowering drug of the meglitinide class used in the 
management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes 
mellitus or NIDDM). This class was developed to specifically control meal-related (prandial) 
glucose fluctuations in patients with type 2 diabetes mellitus. Like the sulphonylureas, they 
reduce blood glucose by stimulating insulin secretion. Repaglinide was approved by FDA in 
1997. 
 
STRUCTURAL FORMULA: 
  
 
 
EMPIRICAL FORMULA: 
• C27 H36 N2 O4 
 
CHEMICAL NAME:  
• S (+) 2-ethoxy-4(2((3-methyl-1-(2-(1-piperidinyl) phenyl)-butyl) amino)-2-
oxoethyl) benzoic acid. 
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DESCRIPTION: 
• Nature   : Repaglinide is a white to off-white powder 
• Solubility  : 2.94e-03 mg/mL 
• Melting point  : 130 to 131 0C 
• Molecular weight : 452.6 
 
SOLUBILITY: 
• Freely soluble in methanol. 
• Soluble in dichloromethane. 
• Insoluble in water 
CHEMICAL PROPERTIES: 
Loss on drying 
• Not more than 0.7% 
Residue on ignition 
• Not more than 0.1% 
Heavy metals 
• Less than 0.001% 
 
MECHANISM OF ACTION: 
Repaglinide acts by stimulating release of insulin from the β cells of the islets of 
pancreas inhibiting ATP-sensitive K+ channels, thereby activating the Ca++ channels with 
increase in intracellular calcium to release insulin. However, repaglinide acts on a different 
binding site than the sulphonylureas. Repaglinide is not effective in the absence of functioning 
beta-cells. The ion channel mechanism is highly tissue selective with low affinity for heart 
and skeletal muscle. 
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PHARMACOKINETICS: 
 
Absorption:  
     After oral administration, repaglinide is rapidly and completely absorbed from the 
Gastrointestinal tract. After single and multiple oral doses in healthy subjects or in patients, 
peak plasma drug levels (Cmax) occur within 1 hour (Tmax). Repaglinide has a plasma half-
life of approximately 1 hour. The mean absolute bioavailability ranges from 56% to 
63%.When repaglinide was given along with food the mean Tmax was not changed but the 
mean Cmax and AUC was decreased by 20% and 12% respectively.  
 
Distribution:  
The volume of distribution at steady state (Vss) was 31 L, and the total body clearance 
(CL) was 38 L/h. Protein binding and binding to human serum albumin was greater than 98%. 
 
Metabolism:  
    Repaglinide is completely metabolized by oxidative biotransformation and direct 
conjugation with glucuronic acid after either an IV or oral dose. The major metabolites are an 
oxidized dicarboxylic acid, the aromatic amine, and the acyl glucuronide. The cytochrome P-
450 enzyme system, specifically 2C8 and 3A4, have been shown to be involved in the N-
dealkylation of repaglinide to oxidized dicarboxylic acid and the further oxidation to aromatic 
amine. Metabolites do not contribute to the glucose-lowering effect of repaglinide. 
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Excretion: 
Within 96 hours after dosing with 14C-repaglinide as a single, oral dose, approximately 
90% of the radiolabel was recovered in the feces and approximately 8% in the urine. Only 
0.1% of the dose is cleared in the urine as parent compound. The major metabolite oxidized 
dicarboxylic acid accounted for 60% of the administered dose. Less than 2% of parent drug 
was recovered in feces. 
 
INDICATIONS AND USAGE: 
• Repaglinide is indicated as an adjunct to diet and exercise to lower the 
blood glucose in patients with type 2 diabetes mellitus. 
• Also indicated for combination therapy use with metformin or 
thiazolidinediones. 
• If this treatment program fails to reduce symptoms and/or blood glucose, 
the use of an oral blood glucose-lowering agent or insulin should be 
considered. 
 
DOSE: 
The recommended dose range is 0.5 mg to 4 mg taken with meals. Repaglinide may be 
dosed preprandially 2, 3, or 4 times a day in response to changes in the patient’s meal pattern. 
The maximum recommended daily dose is 16 mg. 
For patients not previously treated or whose glycosylated haemoglobin level (HbA1c) 
is < 8%, the starting dose should be 0.5 mg with each meal. For patients previously treated 
with blood glucose-lowering drugs and whose HbA1c is > 8%, the initial dose is 1 or 2 mg 
with each meal preprandially. 
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There is no fixed dosage regimen for the management of type 2 diabetes with 
Repaglinide. The patient's blood glucose should be monitored periodically to determine the 
minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of 
blood glucose at the maximum recommended dose of medication; and to detect secondary 
failure, i.e., loss of an adequate blood glucose-lowering response after an initial period of 
effectiveness. Glycosylated hemoglobin levels are of value in monitoring the patient's longer 
term response to therapy. 
When transferred from longer half-life sulfonylurea agents to repaglinide, close 
monitoring may be indicated for up to one week or longer. Patients should then be observed 
carefully for hypoglycemia due to potential overlapping of drug effects. 
 
ADVERSE EFFECTS: 
Common adverse events: 
The most common adverse events leading to withdrawal were hyperglycemia, 
hypoglycemia, and related symptoms.  
The incidence cardiovascular events like hypertension, abnormal EKG, myocardial 
infarction, arrhythmias, and palpitations were ≤ 1%. 
The incidence of total serious cardiovascular adverse events, including ischemia, was 
higher for repaglinide than for sulfonylurea drugs in controlled comparator clinical trials. 
 
Infrequent Adverse Events (<1% of Patients): 
Postmarketing experience includes reports of rare adverse events like alopecia, 
hemolytic anemia, pancreatitis, Stevens - Johnson syndrome, and severe hepatic dysfunction 
including jaundice and hepatitis. 
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GI events      : nausea, diarrhea, constipation, vomiting and dyspepsia. 
 Musculoskeletal events   : arthralgia and backpain. 
 Respiratory events     : sinusitis, rhinitis, bronchitis. 
 
Drug-Drug interactions: 
Repaglinide is metabolized by cytochrome P450 enzymes 2C8 and 3A4. 
Consequently, repaglinide metabolism may be altered by drugs which influence these 
cytochrome P450 enzyme systems via induction and inhibition. Caution should therefore be 
used in patients who are on repaglinide and taking inhibitors and/or inducers of CYP2C8 and 
CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time 
resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known 
to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial 
agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like 
trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 
enzyme systems include rifampin, barbiturates, and carbamezapine.  
Contraindications: 
Repaglinide is contraindicated in patients with, 
1. Diabetic ketoacidosis, with or without coma. 
2. Type1 diabetes. 
3. Known hypersensitivity to the drug or its inactive ingredients. 
Storage: 
• Do not store above 25° C (77° F).Protect from moisture. Keep containers tightly 
closed. 
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CHAPTER VIII 
EXCIPIENTS PROFILE 
POLOXAMER 188 44 
SYNONYM  
 Lutrol F 68, Pluronic F 68 
 
STRUCTURE 
 
 
CHEMICAL NAME 
 
 Polyethylene-Polypropylene Glycol 
 
EMPIRICAL FORMULA 
 HO(C2H4O)a(C3H6O)b(C2H4O)aH 
 
MOLECULAR WEIGHT 
 8400 
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FUNCTIONAL CATEGORY 
 Emulsifying agent 
 Sensitize drug resistant cancers to chemotherapy 
 
DESCRIPTION 
 White to off white granules 
 
PROPERTIES 
 Physical state  : white powder 
 Solubility in water : soluble in water 
 Solvent solubility : soluble in methanol and chloroform mixture 
 HLB value  : 29.0 
 
BIOLOGICAL EFFECTS OF POLOXAMER 
Originally thought to be inert carrier molecules work led by Kabanov has recently shown 
that some of these polymers have a very real effect on biological systems independently of the 
drug they are transporting. The poloxamers have been shown to incorporate into cellular 
membranes affecting the microviscosity of the membranes. 
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STABILITY AND STORAGE CONDITIONS 
It is stable under ordinary conditions, and should be stored in a well-closed container and 
protected from light. 
SAFETY 
It is generally regarded as an essentially non-toxic and non-irritant material at the levels 
employed as an excipients. 
HANDLING PRECAUTIONS 
Keep away from heat. Keep away from sources of ignition. Empty containers pose a fire 
risk; evaporate the residue under a fume hood. Ground all equipment containing material. Do not 
breathe dust. 
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PEG-6000   
SYNONYM 
Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG; Pluriol E; polyoxyethylene glycol. 
 
STRUCTURE 
                    
CHEMICAL NAME 
 
 a-Hydro-o-hydroxypoly(oxy-1,2-ethanediyl) 
 
 
EMPIRICAL FORMULA 
 HOCH2 (CH2OCH2)mCH2OH  
Where m represents the average number of oxyethylene groups. Alternatively, the general 
formula H(OCH2CH2)nOH may be used to represent polyethylene glycol, where n is a number m 
in the previous formula +1. 
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MOLECULAR WEIGHT 
 6000 
 
FUNCTIONAL CATEGORY 
Ointment base; plasticizer; solvent; suppository base; tablet and capsule lubricant. 
DESCRIPTION 
The USPNF 23 describes polyethylene glycol as being an addition polymer of ethylene 
oxide and water. Polyethylene glycol grades 200–600 are liquids; grades 1000 and above are 
solids at ambient temperatures. Solid grades (PEG>1000) are white or off-white in color, and 
range in consistency from pastes to waxy flakes. They have a faint, sweet odor. Grades of PEG 
6000 and above are available as free-flowing milled powders. 
PROPERTIES 
 Physical state  : white flakes 
 Solubility in water : soluble in water 
 Solvent solubility : soluble in methanol,ethanol(95%),dichloromethane,    
                                                            and acetone.    
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HANDLING PRECAUTION 
Observe normal precautions appropriate to the circumstances and quantity of   material 
handled. Eye protection is recommended         
STABILITY AND STORAGE CONDITIONS 
Polyethylene glycols are chemically stable in air and in solution; Polyethylene glycols 
should be stored in well-closed containers in a cool, dry place. 
SAFETY 
Polyethylene glycols are widely used in a variety of pharmaceutical formulations. 
Generally, they are regarded as nontoxic and nonirritant materials. Adverse reactions to 
polyethylene glycols have been reported, the greatest toxicity being with glycols of low 
molecular weight. However, the toxicity of glycols is relatively low.     
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PVP K 30 44 
 
SYNONYM 
Kollidon, Plasdone; poly [1-(2-oxo-1-pyrrolidinyl) ethylene]; Polyvidone; Polyvinylpyrrolidone; 
PVP; 1-vinyl-2-pyrrolidinone polymer. 
 
STRUCTURE 
                                         
CHEMICAL NAME 
 
 1-Ethenyl-2-pyrrolidinone homopolymer 
 
EMPIRICAL FORMULA 
 (C6H9NO)n               2500–3 000 000 
 
MOLECULAR WEIGHT 
 50000 
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FUNCTIONAL CATEGORY 
 Disintegrant; dissolution aid; suspending agent; tablet binder 
 
DESCRIPTION 
Povidone occurs as a fine, white to creamy-white colored, odorless or almost odorless, 
hygroscopic powder. 
 
PROPERTIES 
 Physical state           : white powder 
 Solubility                        : freely soluble in acids, chloroform, ethanol (95%),  
      Ketones. 
  Ethanol and water         : practically insoluble in ether, hydrocarbons, and 
    mineral oil.     
 
HANDLING PRECAUTIONS 
Observe normal precautions appropriate to the circumstances and quantity of material 
handled. Eye protection is recommended 
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STABILITY AND STORAGE CONDITIONS 
Povidone may be stored under ordinary conditions without undergoing decomposition or 
degradation. However, since the powder is hygroscopic, it should be stored in an airtight 
container in a cool, dry place. 
 
SAFETY 
Povidone is widely used as an excipient, particularly in oral tablets and solutions. When 
consumed orally, povidone may be regarded as essentially nontoxic since it is not absorbed from 
the gastrointestinal tract or mucous membranes. Additionally it has no irritant effect on the skin 
and causes no sensitization. 
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CROSPOVIDONE 44 
 
SYSNONYM 
 Cross linked povidone 
 
 Kollidon CL 
 
 Polyvinyl polypyrrolidone 
 
 
STRUCTURE 
 
 
 
 
 
CHEMICAL NAME 
 1-Ethenyl – 2 – Pyrrolidinone homopolymer. 
 
 
EMPRRICAL FORMULA 
 (C6 H9 NO)n 
 
 48 
MOLECULAR WEIGHT 
 
> 1000 000 
 
FUNCTIONAL CATEGORY 
 Tablet disintegrant 
 
DESCRIPTION 
 White to creamy white powder. 
 
PROPERTIES 
 Physical state: White powder 
 
 Solubility in water; insoluble in water 
 
 Solvent solubility: Soluble in methanol and dichloromethane 
 
STABILITY AND STORAGE CONDITIONS 
 Crospovidone is hygroscopic; it should be stores in an airtight container in a bol, dry 
place. 
 
SAFETY 
 Crospovidone is use in oral pharmaceutical formulations and is generally regarded as a 
nontoxic and non irritant material. 
 
HANDLING PRECAUTIONS 
 Eye protection, gloves and a dust mask are recommended. 
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CHAPTER IX 
EXPERIMENTAL DETAILS 
PREPARATION OF CALIBRATION CURVE FOR REPAGLINIDE 
PREPARATION OF DISSOLUTION MEDIUM:45 
CITROPHOSPHATE BUFFER PH 5: 
10.2g of citric acid monohydrate and 18.16g of dibasic sodium phosphate are dissolved in 
1L of distilled water. 
Preparation of Calibration Curve for REPAGLINIDE:53 
To a quantity of 100mg of repaglinide, 5ml of methanol is added and the volume is made 
up to 100ml with methanol. Dilutions are made to get the concentration of 1-10 µg/ml 
respectively. The solution is scanned in (UV) spectrophotometer and the λ max is found to be 
283nm.The absorbance’s of the solutions are measured at the λ max . 
The calibration graph is drawn by taking the concentration on X axis and respective 
absorbance in Y axis, to get a straight line as per like Beers law. This standard curve is used to 
estimate the concentration of the drug release from the formulation during the in vitro dissolution 
studies. 
PREPARATION OF REPAGLINIDE SOLID DISPERSION FORMULATION: 14,15 
Solid dispersions are prepared with the drug repaglinide and polymers (PEG 6000,      
PVP K30, Poloxamer 188, Crospovidone) using 1:1,1:2, 1:4, and 1:6 weight ratios by means of 
solvent evaporation and melting methods. Physical mixtures are prepared by mixing manually. 
The mixtures are passed through a sieve no.120.  
 50 
Melting method17,19 ,34,38: 
PEG 6000 is melted in a water bath at 700c, the drug repaglinide added in the solid state 
and the mixture is stirred well until homogeneity would be attained. The mixture allowed to cool 
slowly at room temperature. 
Poloxamer 188 is heated at temp of 550c using a thermostatically controlled water bath. 
Then the drug repaglinide is dispersed in the ratios 1:1, 1:2, 1:4, and 1:6 in the melted carrier 
poloxamer 188. The resultant mixture is cooled in an ice water mixture and maintained at the 
cold temp for 2 hrs. 
The solidified mass is removed from the ice water mixture and allowed to attain the room 
temperature (25-300c). It is stored at room temperature for 24 hrs, and then pulverized using a 
glass mortar and pestle. The pulverized mass sifted through a no.120 sieve and then weighed, 
and transferred to an amber coloured bottle. 
Solvent Evaporation Method26,27,28: 
Repaglinide and PEG 6000, PVP K30, Poloxamer 188, Crospovidone are taken in the 
ratios of 1:1, 1:2, 1:4, and 1:6 separately. Then the mixtures are triturated and dissolved in 
methanol. The solutions are evaporated at 400 C, the residual mass scraped and sifted through 
sieve no.120 and kept in desiccator for drying (Table 1).  
 DRUG CONTENT ANALYSIS 
Solid dispersions equivalent to 2mg of Repaglinide are taken and dissolved in minimum 
quantity of methanol and volume is made up to 50ml. From this solution, aliquot is taken and 
again diluted with methanol up to 50ml. The solution is assayed for drug content using UV-
spectrophotometer method by measuring the absorbance at 283 nm. 
 51 
INVITRO RELEASE STUDIES 45,51,53,35: 
In-vitro release studies of Repaglinide is performed by using USP type I basket 
dissolution apparatus in 900 ml of citro phosphate buffer pH 5 maintained at 37° C ± 1° C and  
75 rpm. Samples (10 ml) are withdrawn at regular intervals of 5 minutes for 1hr and the same 
volume of fresh dissolution medium is replaced after every withdrawal. The withdrawn samples 
are analyzed by U.V. visible spectrophotometer at λ max 283 nm.  
The above procedure is performed with repaglinide solid dispersion formulations.  
FT-IR STUDIES ;32,33  
The possibility of drug-excipient interactions are further investigated by FT-IR. The FT-
IR graph of pure drug and combination of drug with excipient are recorded .The analysis is 
performed by using Shimadzu FT-IR Spectrometer. The scanning range is 450-4000 cm-1 and the 
resolution is 4cm-1. Samples are prepared in KBr pellets. 
POWDER X-RAY DIFFRACTION (PXRD) STUDIES; 36,37,39,19 
X- ray diffraction measurements of the solid dispersions are performed on a Rigaku X- 
ray generator (Japan) with a copper anode (cu Kά radiation, λ = 1.540598 nm, 40 kV), over the 
2θ range of 10-700 to find out the crystalline nature of pure drug and solid dispersed 
formulations. 
 
SOLUBILITY STUDIES34,29,30,31 
 Excess (usually more than 1mg/ml concentration) of solid dispersion, and physical 
mixture, pure drug are added to 25ml distilled water taken in stoppered conical flask, vortexed 
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for 2 minutes and shaken at (Mechanical Shaker) 24 hours.  Resultant samples containing 
undissolved solid dispersions suspended in the test medium are centrifuged at 10,000rpm for 5 
minutes and the clear supernatant obtained are filtered (whatman), suitably diluted with distilled 
water and analyzed spectrophotometrically at 283nm. 
DSC STUDIES18,19 
DSC is performed using Perkin Elmer STA 6000 Thermal Analyzer. The instrument is 
calibrated with indium standard. Accurately weighed (it varies from 3mg-25mg) samples are 
placed in an open type ceramic sample pans. Thermo grams are obtained by heating the sample 
at a constant heating rate of 8ºC/minute. A dry purge of Argon gas (60ml/min) is used for all 
runs. Samples are heated from 37°C-400°C. 
 
STABILITY STUDY 21,22 
The stability of repaglinide solid dispersion was monitored up to 45 days at ambient 
temperature and relative humidity (40°C/60%RH). Periodically samples were withdrawn and 
characterized by dissolution rate measurements. 
PREPARATION OF TABLETS54: 
Of all the formulations, selected solid dispersion (SEM 7) is compressed into tablets.  
These tablets had a theoretical repaglinide content of 2mg.  Lactose is added as tablet diluents.  
The solid dispersion are blended with talc and magnesium stearate (1% of the total weight of the 
mixture) and compressed into tablet with a total weight of 200mg.  As a reference, tablets from a 
plain drug (ie. Without any polymer) are made to compare the dissolution behaviour of both the 
formulations. 
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CHAPTER X 
RESULTS AND DISCUSSION 
 
STANDARD CURVE OF REPAGLINIDE:  
The λ max of Repaglinide was determined by scanning the 10µg/ml of the drug solution 
in citro phosphate buffer solution pH 5. It showed the λ max of 283nm in methanol and citro 
phosphate buffer solution pH 5.  
Linear correlation coefficient was obtained for calibration of Repaglinide. Repaglinide 
obeys the beer’s law within the concentration range of 1 to 10 µg/ml. Calibration plots of 
Repaglinide in citro phosphate buffer solution pH 5 medium was shown in  Figure 3 & Table 2.  
 
 FORMULATION OF REPAGLINIDE SOLID DISPERSIONS:47,48,49 
 In the present study, twenty four formulations of Repaglinide were prepared by using 
water soluble carriers (PEG 6000, Poloxamer 188,Cros povidone, PVP K30) in the ratios of (1:1, 
1:2, 1:4, and 1:6) in two methods (Melting Method and Solvent Evaporation Method) with the 
concentration of the drug being constant (2 mg) (and are shown in Table no: 1). The prepared 
solid dispersions were found to be uniform and homogenous in appearance.  
 PEG 6000 and Poloxamer 188 were prepared by both melting method and solvent 
evaporation methods.  Cros povidone, PVP K
 30 were used only in the solvent evaporation 
method since it is hygroscopic. 
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DRUG CONTENT 
 The drug content of the prepared solid dispersion was found to be in the range of (94.45-
98.97%) indicating the applications of the present method for the preparation of solid dispersion 
with high content uniformity (Table: 3). 
INVITRO RELEASE STUDIES 45,51,53  
In vitro release profile showed that the formulations MM3, MM7, SEM3, SEM7, 
SEM11, SEM15, and SEM19 showed faster drug release when compared to other formulations 
(all prepared with 1:4 ratio).   The results indicated that increasing the polymer concentration 
will increase the dissolution of the drug. Of the selected formulations those prepared with                              
PVP K 30 showed desired release profile when compared to other polymers (PEG 6000, 
Poloxamer 188 and Cros povidone).  Among the formulations SEM7 (PVPK30 1:4) was selected 
as a best formulations (Table 4 & Figure 5-10).    
FTIR STUDIES 49,50,51  
FTIR spectra for pure drug, polymers used and the formulations containing 1:1 ratio of 
drug and polymers were estimated. Repaglinide pure drug shows the bond vibrations at 3616 cm-
1
 ( NH stretching), 3307 cm-1 (C-H stretching), 1446 cm-1 ( O-H stretching), 1334 cm-1 (C-H 
stretching), and 1035 cm-1 ( C-0 stretching). The bond vibrations of poloxamer shows at 3307 
cm-1 (C-H stretching) and 1344 cm-1 ( C-H bending),  crospovidone at 3428 cm-1 (C-H 
stretching), 1598  cm-1 (C-H bending),  PEG 6000 at 3307 cm-1 (C-H stretching), 1344  cm-1 (C-
H bending), and PVP K 30 2933 cm-1 (C-H stretching),1566  cm-1 (C-H bending).  
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The results of IR studies revealed that there is no interaction between carrier and drug in 
the formulations. The results of IR studies are shown in Figure: 13A-I 
POWDER X-RAY DIFFRACTION (PXRD) STUDIES 53,54                    
The X- ray diffraction pattern of Repaglinide exhibited sharp, highly intense and less 
diffused peaks indicating the crystalline nature of drug, as shown in Figure: 7, but in the 
formulations no characteristic diffraction peaks were seen for the drug. It was revealed the 
crystallinity of the drug was highly reduced indicating the drug was converted to its amorphous 
form (Figure 15).  
 
DIFFERENTIAL SCANNING CALORIMETRY 51,52 
Thermal behavior of pure drug and corresponding drug carrier system are depicted in 
Figure 2.  The DSC curve of repaglinide profiles sharp endothermic peak (131.80c)               
corresponding to its melting point, indicating its crystalline nature.  However, the characteristic 
endothermic peak, corresponding to drug was broadened and shifted toward lower temperature, 
with reduced intensity in solid dispersions.  This could be attributed to higher polymer 
concentration and uniform distribution of drug in the crust of polymer, resulting in complete 
miscibility of drug in polymer.  Moreover, the data also indicate there seems to be no interaction 
between the drug and polymer (Figure 14).  
DRUG SOLUBILITY 50,54 
The equilibrium solubility was determined after 24hours.  The solubility of repaglinide in 
water is known to be 2.94µg/ml at ambient temperature.  The physical mixture, formulation were 
found to have more solubility when compared to pure drug 
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Form of drug 
 
Solubility (µg/ml) ± SD 
 
Pure drug 
 
Physical Mixture 
 
Solid dispersion 
 
2.94 ± 0.11 
 
4.86 ± 0.12 
 
8.74 ± 0.15 
 
STABILITY STUDY 16,20 
Optimized solid dispersion formulation SEM 7 was subjected to stability studies and 
there was no significance change in the drug content for 45 days at 40°C and 60% RH. SEM 7 
was found to be physicochemically stable and shown best release. (Table No.5) 
COMPARISON OF TABLET FORMULATION 54 
The dissolution studies on the solid dispersed tablet and plain tablet were performed in 
citro-phosphate buffer pH 5 using USP-2(Paddle type). 
In vitro release profile of solid dispersion tablets showed a more rapid dissolution of 
repaglinide than that of plain tablet (Figure 11 & 12). 
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CHAPTER- XI 
SUMMARY AND CONCLUSION 
 The purpose of this study was to prepare solid dispersions of Repaglinide to 
improve the solubility there by enhance the bioavailability. 
 
 Melting Method and Solvent Evaporation Method were employed to prepare solid 
dispersions. 
 
 The formulated solid dispersions were characterized for in vitro release studies in 
citro phosphate buffer PH 5. 
 
 The invitro release studies revealed that the increase in the carrier concentration 
increases the dissolution rate. Faster dissolution rate was observed in the order of   
                         PVP K30
 
> PEG 6000 > Polaxamer 188 >Crospovidone. 
 
 DSC and FT-IR studies of the all formulations showed that there is no interaction 
between the drug and the carriers. 
 
 The results of the Powder X-ray diffraction (PXRD) studies proved that 
crystallinity of repaglinide was remarkably reduced in the best formulation    (PVP K30 1:4 ratio). 
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CONCLUSION: 
It is concluded that the melting method and solvent evaporation method, are useful 
methods for the successful enhancement of solubility of poorly water soluble drug repaglinide 
with faster dissolution rate. But from the evidence of PXRD studies, the crystallinity of the drug 
was much reduced in SEM 7 compare to other 6 formulations.  Further, it may be assumed that 
the bioavailability may be increased due to the conversion of crystalline matter into amorphous 
powder. Hence we can conclude that solid dispersions of repaglinide by using the water soluble 
carrier PVP K30 in the ratio 1:4 prepared by solvent evaporation method provide best drug 
release (100.2% released in30 mins) among all the selected 6 formulations, and this technique 
scan be used to enhance the bioavailability of poorly water soluble drugs like repaglinide. 
. 
  
 
 
 
 
 
 
 
 
 
 
 
TABLE: 1 
MELTING METHOD 
S.NO 
 
NAME OF THE  
FORMULATION 
RATIO OF THE DRUG 
AND CARRIER 
NAME OF THE 
CARRIER USED 
1 MM 1 1 : 1 PEG 6000 
2 MM 2 1 : 2 PEG 6000 
3 MM 3 1 : 4 PEG 6000 
4 MM 4 1 : 6 PEG 6000 
5 MM 5 1 : 1 POLOXAMER 188 
6 MM 6 1 : 2 POLOXAMER 188 
7 MM 7 1 : 4 POLOXAMER 188 
8 MM 8 1 : 6 POLOXAMER 188 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOLVENT EVAPOPRATION METHOD 
 
S.NO 
 
NAME OF THE  
FORMULATION 
RATIO OF THE DRUG 
AND CARRIER 
NAME OF THE CARRIER 
USED 
1 SEM 1 1 : 1 PEG 6000 
2 SEM 2 1 : 2 PEG 6000 
3 SEM 3 1 : 4 PEG 6000 
4 SEM 4 1 : 6 PEG 6000 
5 SEM 5 1 : 1 PVP K30 
6 SEM 6 1 : 2 PVP K30 
7 SEM 7 1 : 4 PVP K30 
8 SEM 8 1 : 6 PVP K30 
9 SEM 9 1 : 1 POLOXAMER 188 
10 SEM 10 1 : 2 POLOXAMER 188 
11 SEM 11 1 : 4 POLOXAMER 188 
12 SEM 12 1 : 6 POLOXAMER 188 
13 SEM 13 1 : 1 CROSPOVIDONE 
14 SEM 14 1 : 2 CROSPOVIDONE 
15 SEM 15 1 : 4 CROSPOVIDONE 
16 SEM 16 1 : 6 CROSPOVIDONE 
 
 
 
 
 
 
 
TABLE: 2 
CALIBRATION OF REPAGLINIDE 
S.NO CONCENTRATION (µg/ml) ABSORBANCE±SD* 
1 1 0.009 ± 0.000 
2 2 0.019± 0.002 
3 3 0.029± 0.002 
4 4 0.039± 0.001 
5 5 0.048± 0.001 
6 6 0.059 ± 0.001 
7 7 0.069± 0.001 
8 8 0.079 ± 0.002 
9 9 0.088 ± 0.001 
                     γ = 0.9999 
 
 
 
 
 
 
 
 
 
 
TABLE: 3 
S.NO FORMULATIONS DRUG CONTENT±SD* 
1 MM 1 98.97 ± 0.355 
2 MM 2 96.90 ± 0.355 
3 MM 3 95.90 ± 0.355 
4 MM 4 94.94 ± 0.941 
5 MM 5 97.97 ± 0.410 
6 MM 6 96.96± 0.410 
7 MM 7 95.97 ± 0.541 
8 MM 8 .96.96 ± 0.613 
9 SEM 1 95.92 ± 0.410 
10 SEM 2 96.91 ± 0.203 
11 SEM 3 95.92 ± 0.203 
12 SEM 4 94.95 ± 0.203 
13 SEM 5 96.94 ± 0.207 
14 SEM 6 95.99 ± 0.203 
15 SEM 7 96.98 ± 0.207 
16 SEM 8 97.92 ±  0.207 
17 SEM 9 97.97 ± 0.203 
18 SEM 10 97.94 ± 0.207 
19 SEM 11 96.93 ± 0.207 
20 SEM 12 95.95 ± 0.203 
21 SEM 13 94.94 ± 0.201 
22 SEM 14 96.95 ± 0.613 
23 SEM 15 97.99 ± 0.207 
24 SEM 16 95.91 ± 0.410 
          
 
 
 
 
 
TABLE: 4A 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 
PURE 
DRUG MM 1 MM 2 MM 3 MM 4 
5 0 13.2 ± 2.12 13.2 ± 2.12 31.2 ± 2.16 19.2 ± 2.12 
10 0 17.7 ± 2.09 16.3 ± 0.00 41.9 ± 2.14 29.9 ± 0.04 
15 0 25.4 ± 0.00 25.4 ± 0.00 48.1 ± 0.09 34.5 ± 0.00 
20 0 30.1 ± 0.04 33.0 ± 2.14 56.0 ± 2.12 46.7 ± 2.12 
25 0 36.2 ± 1.90 40.7 ± 2.09 65.3 ± 2.09 59.1 ± 2.20 
30 0 45.4 ± 2.12 54.5 ± 2.14 71.7 ± 0.08 66.9 ± 0.00 
35 13.2 ± 2.12 48.7 ± 0.04 59.1 ± 1.93 79.5 ± 2.30 74.1 ± 1.83 
40 20.8 ± 3.60 58.0 ± 0.00 68.7 ± 2.12 89.1 ± 2.12 87.1 ± 2.02 
45 25.5 ± 3.73 68.8 ± 2.14 77.9 ± 2.28 99.8 ± 0.16 90.6 ± 0.09 
50 31.6 ± 5.62 76.5 ± 0.04 81.5 ± 0.04 95.9 ± 0.08 95.7 ± 0.21 
55 39.3 ± 3.73 83.2 ± 2.09 96.8 ± 2.23 94.9 ± 2.02 100.5 ± 0.16 
60 48.5 ± 0.12 91.2 ± 0.04 91.5 ± 0.04 92.6 ± 0.08 96.5 ± 0.16 
                  
  
 
 
 
 
 
 
 
 
 
TABLE: 4B 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 MM 5 MM 6 MM 7 MM 8 
5 11.7 ± 0..00 13.2 ± 2.12 11.7 ± 0.00 17.7 ± 2.12 
10 16.3 ± 0.00 17.7 ± 2.09 13.3 ± 2.10 25.3 ± 0.04 
15 24.8 ± 2.80 25.4 ± 0.00 29.9 ± 0.00 28.5 ± 2.12 
20 30.1 ± 0.00 30.1 ± 0.04 39.1 ± 0.00 34.6 ± 0.04 
25 36.2 ± 2.12 36.2 ± 1.90 45.3 ± 2.10 43.9 ± 0.04 
30 43.9 ± 0.00 45.4 ± 2.12 66.4 ± 0.30 53.2 ± 0.04 
35 50.2 ± 2.12 48.7 ± 0.04 71.5 ± 0.00 61.1 ± 2.19 
40 58.0 ± 0.00 58.00 ± 0.00 74.8 ± 1.80 67.3 ± 0.00 
45 65.9 ± 2.05 68.8 ± 2.14 90.4 ± 0.00 76.5 ± 0.04 
50 76.5 ± 0.00 76.5 ± 0.04 92.4 ± 2.10 84.6 ± 2.00 
55 81.7 ± 0.00 83.2 ± 2.09 95.9 ± 0.00 88.7 ± 1.8 
60 86.6 ± 0.00 91.2 ± 0.04 96.4 ± 0.00 96.1 ± 0.00 
 
 
 
 
 
 
 
 
 
 
 
                                                              TABLE: 4C 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 SEM 1 SEM 2 SEM 3 SEM 4 
5 17.7 ± 2.12 26.7 ± 2.16 41.3±2.16 22.2 ±2.12  
10 25.3 ± 0.04 28.4 ± 2.12 49.5±2.10 29.9 ± 0.04 
15 34.5 ± 3.60 42.1 ± 2.12       60.5 ± 2.26 40.6 ± 2.12 
20 45.2 ± 2.16 48.4 ± 0.09 77.0 ±2.28 49.8 ± 2.16 
25 54.5 ± 2.12 54.6 ± 2.12 89.7 ± 0.00 54.6 ± 2.16 
30 62.5 ±0 .00 59.4 ± 2.12 98.1 ± 0.00 57.9 ± 0.00 
35 74.5 ± 2.00 67.4 ± 0.08 100.3 ± 0.00 71.7 ± 0.00 
40 87.2 ± 2.12        79.7 ± 2.14 99.8 ± 2.1 88.7 ± 2.14 
45  93.6± 2.07 90.0 ± 1.06 99.0 ± 0.1    96.7 ± 2.12 
50 95.6  ± 0.00 95.8 ± 2.00 98.1± 0.00 97.2 ± 2.16 
55 98.6 ± 0.00 100.3 ± 2.16 97.5 ± 2.02 99.2 ± 2.00 
60 99.3 ± 0.28 99.5 ± 0.1 97.0 ± 0.08 99.7± 2.00 
                    
 
 
 
 
 
 
 
 
 
 
TABLE: 4D 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 SEM 5 SEM  6 SEM  7 SEM 8 
5 34.3 ± 0.00 44.7 ± 2.12 58.4 ± 2.26 25.2 ± 0.00 
10 42 ± 2.12 49.6 ± 2.10 70.6 ± 0.00 43.4 ± 0.00 
15 48.2 ± 0.00 62.0 ± 0.00 83.1 ± 2.1 49.6 ± 2.16 
20 67.8 ± 2.2 78.7 ± 2.2 94.1 ± 0.00 69.5 ± 2.12 
25 70.14 ± 0.00 89.7 ± 0.00 99.7 ± 0.00 89.1 ± 0.49 
30 82.4 ± 2.12 97.6 ± 2.00 100.2 ± 1.1 94.4 ± 0.00 
35 88.8 ± 2.14 99.2 ± 0.21 99.5 ± 2.30 98.7 ± 0.96 
40 99.8 ± 0.00     100.2 ± 2.12 98.7 ± 2.12 100.02 ± 0.00 
45 100.9 ± 0.00 99.95 ± 2.28 97.6 ± 0.16 98.5 ± 2.00 
50 99.8 ± 0.00 98.50 ± 0.04 95.93 ± 0.08 97.3 ± 0.21 
55 96.9 ± 0.00 96.7 ± 0.14 94.97 ± 2.02 96.7 ± 0.16 
60 94.4 ± 2.00 95.44 ± 0.04 93.63 ± 0.08 96.59 ± 0.16 
                    
 
 
 
 
 
 
 
 
 
 
TABLE: 4E 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 SEM 9 SEM 10 SEM 11 SEM 12 
5 11.7 ± 0.00 16.2 ± 0.00 34.2 ± 0.00 16.2 ± 0.00 
10 13.3 ± 2.1 29.8 ± 0.00 43.4 ± 0.00 23.8 ± 2.1 
15 29.9 ± 0.00 36.0 ± 2.1 49.7 ± 2.1 25.5 ± 0.00 
20 39.1 ± 0.00 46.7 ± 2.1 69.5 ± 2.1 34.6 ± 0.00 
25 45.3 ± 2.1 57.5 ± 0.00 71.4 ± 0.00 43.9 ± 0.00 
30 66.4 ±0 .3 66.9 ± 0.00 80.9 ± 0.00 53.1 ± 0.00 
35 71.5 ± 0.00 71.7 ± 0.00 88.8 ± 2.00 56.4 ± 2.1 
40 74.8 ± 1.8         85.7± 0.00 95.1 ± 0.1 77.6 ± 2.2 
45  90.4± 0.00 92.8 ± 1.8 100.2 ± 0.1          81.2 ± 0.00 
50 92.4 ± 2.1 95.8 ± 0.00 96.1 ± 0.00 86.2 ± 0.00 
55 95.9 ± 0.00 100.6 ± 0.14 95.97 ± 2.02 91.2 ± 0.00 
60 96.4 ± 0.00 96.6 ± 0.1 94.63 ± 0.08 94.4 ± 1.9 
                    
 
 
 
 
 
 
 
 
 
 
TABLE: 4F 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 SEM 13 SEM 14 SEM 15 SEM 16 
5 11.7 ± 0.00 20.7 ± 0.00 32.7 ± 2.16 17.7 ± 2.12  
10 16.3 ± 0.00 29.9 ± 0.00 43.5 ± 0.00 25.3 ± 0.04 
15 24.8 ± 2.80 37.5 ± 2.1      48.2 ± 0.08 28.5 ± 2.12 
20 30.1 ± 0.00 48.2 ± 0.00 66.5 ± 3.5 34.6 ± 0.00 
25 36.2 ± 2.12 54.6 ± 2.12 71.4 ± 0.00 43.9 ± 0.00 
30 43.9 ±0 .00 59.4 ± 2.12 80.9 ± 0.00 53.1 ± 0.00 
35 50.2 ± 2.12 70.1 ± 2.00 90.3 ± 0.04 61.1 ± 2.19 
40 58.0 ± 0.00       76.4± 0.00 93.8 ± 2.1 67.3 ± 0.00 
45  65.9± 2.05 81.0 ± 0.04 100.2 ± 0.1       76.5± 0.04 
50 76.5 ± 0.00 88.8 ± 2.00 96.1 ± 0.00 84.6 ± 2.00 
55 81.7 ± 0.00 91.5 ± 0.14 95.97 ± 2.02 88.7 ± 1.80 
60 86.6 ± 0.00 96.5 ± 0.1 94.63 ± 0.08 96.1 ± 0.00 
 
 
TABLE – 5 
STABILITY STUDIES - DRUG CONTENT ESTIMATION 
Formulation 
code 
Percentage drug content. 
0 day 7th day 15th day 30th day 45th day 
MM3 98.54 97.65 97.47 97.94 97.23 
MM7 99.47 98.67 98.71 98.12 97.69 
SEM3 98.57 99.47 98.15 98.97 99.12 
SEM7 97.25 96.98 98.72 99.10 97.15 
SEM11 98.45 98.12 97.69 97.98 98.30 
SEM15 96.15 97.18 97.76 98.92 99.65 
 
 
 
 
 
                    
                                      
 
FIGURE 3 
CALIBRATION OF REPAGLINIDE
CONCENTRATION (µg/ml)
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FIGURE 5 
 
COMPARISON OF INVITRO RELEASE  PROFILE OF VARIOUS RATIOS
OF REPAGLINIDE AND PEG 6000 BY MELTING METHOD.
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FIGURE 6 
COMPARISON OF INVITRO RELEASE  PROFILE OF
 VARIOUS RATIOS OF REPAGLINIDE AND POLOXAMER 188
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FIGURE 7 
COMPARISON OF INVITRO RELEASE  PROFILE OF VARIOUS RATIOS
OF REPAGLINIDE AND PEG 6000.
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FIGURE 8 
COMPARISON OF INVITRO RELEASE  PROFILE OF VARIOUS RATIOS
OF REPAGLINIDE AND PVP K30.
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FIGURE 9 
COMPARISON OF INVITRO RELEASE  PROFILE OF VARIOUS RATIOS OF
REPAGLINIDE AND POLOXAMER188.
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FIGURE 10 
COMPARISON OF INVITRO RELEASE  PROFILE OF VARIOUS RATIOS OF
REPAGLINIDE AND CROSSPOVIDONE.
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FIGURE 11 
 
COMPARISON OF IN-VITRO RELEASE PROFILE OF
MARKETED PRODUCT AND BEST FORMULATION(PVP 1:4)
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FIGURE 12 
COMPARISON OF IN-VITRO RELEASE PROFILE OF PURE
DRUG AND BEST FORMULATION(PVP 1:4)
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FIGURE 13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 14 
DIFFERENTIAL SCANNING CALORIMETRY STUDIES 
 
A. PURE DRUG - REPAGLINIDE  B.  PEG 6000  C. PVP K 30  D. POLOXAMER 188  
 
E. CROSPOVIDONE F. DRUG + PEG 6000 G. DRUG + PVP K30    
H.  DRUG + POLOXAMER 188 I. DRUG + CROSPOVIDONE 
FIGURE 15 
X-RAY DIFFRACTION STUDIES 
 
 
 
A-REPAGLINIDE            B-PEG 6000        C-POLOXAMER   188          D-PVPK30 
E-CROSPOVIDONE             F-DRUG+PEG 6000          G-DRUG+POLOXAMER 
H-DRUG+PVPK30                                                          I-DRUG+CROSPOVIDONE 
 
FIGURE – 13A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE – 13B 
 
 
 
 
FIGURE – 13C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE – 13D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE – 13E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE – 13F 
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